Quote | Super Quote
56064 HS#HSI RP2112X (R BEAR)
RT Nominal up0.305 +0.020 (+7.018%)

14/07/2021 11:16

WuXi Bio (02269) expects 135% increase in interim profit

[ET Net News Agency, 14 July 2021] WuXi Biologics (Cayman) Inc. (02269) said it is
expected that the profit attributable to equity shareholders of the company for the six
months ended 30 June 2021 will increase more than 135% compared with the profit
attributable to equity shareholders of the company for the corresponding period of last
year.
Such increase was primarily attributable to (i) the group's acceleration to undertake,
promptly execute and generate revenue from existing and new COVID-19 projects to support
and enable the group's global clients in the first half of 2021 in combatting against
COVID-19; (ii) leading technology platform, best-in-industry timeline and excellent
execution track record contributing to significantly higher revenue and market share of
new integrated projects; (iii) successful execution of Win-the-Molecule strategy adding
considerable late-stage pipeline and near-term revenue; (iv) the recovery from reduced
productivity due to the brief slow-down in the first quarter of 2020 as disrupted by the
pandemic; (v) the enhancement in the utilization of existing capacities and resources and
the implementation of operational efficiency improvement programs leading to greatly
improved gross margin and operating margin; and (vi) increased investment gains due to the
fair value change of listed and unlisted portfolios held by the group. (RC)

Remark: Real time quote last updated: 24/09/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.